Skip to main content

Prof Reich on the Results of BE-VIVID and BE-READY, Two Phase 3 Clinical Trials on Bimekizumab, an IL-17A/IL-17F Inhibitor

Kristian Reich, MD, PhD, discusses the results of two phase 3 clinical trials, BE-READY1 and BE-VIVID,2 that tested the efficacy and safety of bimekizumab, a novel IL-17A/IL-17F inhibitor. Dr Reich is affiliated with the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation┬« Center in Germany.

Disclosure: Prof Reich was an investigator for both BE READY and BE VIVID.

References
1. Reich K, Papp KA, Blauvelt A, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week phase 3, randomized, double-blinded, ustekinumab- and placebo-controlled study. Presented at: American Academy of Dermatology Virtual Meeting Experience 2020; June 12-14, 2020.
2. Gordon K, Foley P, Krueger J, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE READY, a 56-week phase 3, randomized, double-blinded, placebo-controlled study with randomized withdrawal. Presented at: American Academy of Dermatology Virtual Meeting Experience 2020; June 12-14, 2020.

Back to Top